Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 209646, held by Fresenius Kabi USA. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 209646 (Ephedrine Sulfate), held by Fresenius Kabi USA, was first approved by FDA on Aug 4, 2020, with 1 approved supplement and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
| Sep 13, 2021 | Supplement 1Manufacturing | Approved | None posted |
| Aug 4, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters